News

PMA Insights: Week 7

17/02/2023
  • CEPs Annual Report indicates reduced time to market access
  • The FDA’s Biosimilar User Fee Amendments III (BsUFA III)
15022023-News-Digest-Wk-7Download

Author:

Amy Rudd, ACIM
About the Author

Article Tags

Biosimilars Funding Gene Therapy & ATMPs HTA PMA Trends Pricing

Share this article

Related articles

Insider Insights
09.06.2026
Spain HTA reform 2026: Will Your Evidence Measure ...

Spain has published Royal Decree 415/2026[1], setting out a new national framework for health techno...

Read more
Insider Insights
06.05.2026
Germany’s Draft SHI Reform Bill: Implications fo...

Germany’s draft GKV Contribution Rate Stabilisation Act signals a clearly tighter environment ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch